Maralixibat Chloride

Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D of innovative rare disease therapeutics in China. Velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. WUXI, China and SHANGHAI, May 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its partner CANbridge Pharmaceuticals on the approval of its innovative velaglucerase-beta for injection (Gaurunning) by the China National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above and adults with type I and type III Gaucher disease. This marks China's first and only locally developed enzyme replacement therapy (ERT) for Gaucher disease. Gaucher disease is a rare inherited genetic lysosomal storage disorder characterized by clinical manifestations such as hepatosplenomegaly, anemia, bone pain, and neurological symptoms, which can be life-threatening in severe cases. Recombinant human glucocerebrosidase ERT has been the standard treatment for Gaucher disease for 30 years, significantly improving major non-neurological signs and symptoms, as well as improving the quality of life for patients. It is estimated that the global prevalence of Gaucher disease is 0.7 to 1.75 per 100,000 people. Gaucher disease has been included in China's "First List of Rare Diseases". Velaglucerase-beta for injection is the first collaboration project on rare diseases between CANbridge and WuXi Biologics, advancing from concept to commercialization by leveraging WuXi Biologics' leading integrated technology platform. The project utilized innovative technology to construct high-expression cell line and achieved significant improvements in both yield and quality through WuXiUPTM, an ultra-high productivity continuous bioprocessing platform of WuXi Biologics. The overall yield increased by more than 110 times, and the specific enzyme activity increased by more than 50%, ensuring the affordability for Gaucher disease patients. Additionally, WuXi Biologics developed cell-based bioassay methods for commercial product release and stability testing, addressing the technical challenges of enzyme testing and effectively ensuring product quality control. Additionally, velaglucerase-beta for injection is the first innovative biological product in China to pass segmented manufacturing inspection. Dr. Chris Chen, CEO of WuXi Biologics, stated, "We are honored to enable CANbridge to achieve the significant milestone of approval for velaglucerase-beta for injection, which represents a critical advancement in rare disease drug innovation in China. Developing therapies for rare diseases is a long and challenging journey, requiring relentless joint efforts to bridge the gap between early-stage discovery and patients' access to medication. The successful commercialization of velaglucerase-beta for injection not only reflects CANbridge's decade-long dedication to rare diseases but also exemplifies the value of WuXi Biologics' integrated platform and CRDMO business model. Furthermore, our shared commitment to addressing the unmet clinical needs of rare disease patients has resulted in China's first locally developed ERT for Gaucher disease. We look forward to enabling more global partners to accelerate the development of high-quality rare disease therapies, and making them accessible and affordable for more patients suffering from rare diseases." Dr. James Xue, Founder, Chairman, and CEO of CANbridge Pharmaceuticals, stated, "Enzyme replacement therapy is a crucial part of CANbridge' global pipeline. The approval of velaglucerase-beta for injection in China is a milestone. By leveraging the integrated technology platform, velaglucerase-beta for injection will significantly reduce development costs, making safe and effective domestically produced ERT accessible and affordable for patients. This product is also the first collaboration project between CANbridge and WuXi Biologics in rare diseases. We extend our gratitude to our partners, including WuXi Biologics, who have empowered the development and manufacturing of velaglucerase-beta for injection. This milestone is not only CANbridge' third rare disease drug to be launched following Hunterase® and Livmarli®, but also the first in-house developed commercialized product. In the future, we will continue to focus on the localized research, manufacturing, commercialization, and accessibility of rare disease drugs, bringing innovative treatments to patients in China." Since its establishment, WuXi Biologics has been committed to enabling global innovative biotech companies to accelerate the rare disease drugs from concept to commercialization, benefiting rare disease patients worldwide. As ofthe end of 2024, there are 21 rare disease projects on the company's platform. Additionally, the company actively promotes public awareness and supports the rare disease patient community through various philanthropic initiatives. Its global "Run for Health" campaign has engaged over 2,500 participants to raise awareness for rare diseases. In China, the company's "Rare Disease Student Education Support Program" has provided scholarships to over 100 students affected by rare diseases over the past four years, fostering their academic growth. About Velaglucerase-beta for Injection (Gaurunning) Velaglucerase-beta for injection is the first domestically developed recombinant human glucocerebrosidase ERT in China, now approved for clinical use in treatment of Type I and Type III Gaucher disease patients. Most Gaucher disease patients are Type I and Type III, which are chronic non-neuronopathic and chronic neuronopathic forms, respectively. velaglucerase-beta is administered as an intravenous infusion and is intended to supplement the lack of glucocerebrosidase in the lysosomes of GD patients. The pivotal clinical trial of velaglucerase-beta achieved positive top-line data in August 2024. The velaglucerase-beta pivotal trial is a randomized, double-blind, dose-comparison study designed to evaluate the efficacy, safety, and pharmacokinetics of intravenous velaglucerase-beta administered every other week in newly treated Gaucher Disease (GD) patients, with an extension period. The results demonstrate that the study successfully met its primary efficacy endpoint, showing a statistically significant mean percentage reduction from baseline in spleen volume at nine months for both the 60 U/kg dose (P<0.0001) and the lower 30 U/kg dose (P<0.001). The primary endpoint of this trial protocol has been agreed upon by the CDE. About Gaucher Disease (GD) Gaucher disease, one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. Gaucher disease is a clinical spectrum that comprises Type 0 (perinatal-lethal), Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood. Gaucher disease is caused by a deficiency of glucocerebrosidase (acid b-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms. For 30 years, recombinant human glucocerebrosidase enzyme replacement therapy (ERT) has been the standard of care for Gaucher disease, with clinical trials and real-world data demonstrating significant improvement in the major non-neurological signs and symptoms of disease and quality of life. There were 3,000 patients with Gaucher disease in China in 2020, according to Frost & Sullivan. Gaucher disease has been included in China's "First List of Rare Diseases." About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: . About Canbridge CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 8 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global. For more on CANbridge Pharmaceuticals Inc., please go to: . Contacts Business [email protected] Media [email protected] SOURCE WuXi Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

1在药明生物领先的一体化技术平台的赋能下，注射用维拉苷酶β成功实现从概念到商业化生产2注射用维拉苷酶β作为中国首个，也是目前唯一本土自主开发的戈谢病酶替代疗法药物，标志着北海康成和药明生物在共同促进中国罕见病药物创新研发领域取得重要突破3注射用维拉苷酶β是中国首个通过生物制品分段生产检查的创新生物药无锡和上海，2025年5月16日全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）祝贺合作伙伴北海康成创新罕见病治疗产品注射用维拉苷酶β（商品名：戈芮宁）获中国国家药品监督管理局（NMPA）批准上市，用于治疗12岁及以上青少年和成人I型和III型戈谢病患者。这是中国首个也是目前唯一的本土自主开发的戈谢病酶替代疗法药物。戈谢病是一种罕见的遗传性溶酶体贮积症，患者临床表现包括肝脾肿大、贫血、骨痛和神经系统病变，严重时甚至可能因并发症危及生命。重组人源葡萄糖脑苷脂酶替代疗法 (ERT) 作为戈谢病的标准治疗方案，经过30年的临床应用，在改善患者的主要非神经系统症状以及提高生活质量方面具有显著疗效。据统计，全球平均每10万人中戈谢病患病人数为0.7~1.75。目前，戈谢病已被纳入中国《第一批罕见病目录》。注射用维拉苷酶β是北海康成与药明生物在罕见病领域的首个合作项目，并在药明生物领先的一体化技术平台的赋能下成功实现从概念到商业化。该项目采用创新技术构建了高表达细胞株，并通过药明生物超高效连续生物工艺平台WuXiUP™实现了产量与质量的双重提升，综合产量提升超过110倍，酶比活性提升超过50%，为戈谢病患者用药的可及性提供了保障。同时，药明生物还针对酶类药物特有的检测方法挑战，开发了用于商业化产品放行和稳定性测试的细胞活性检测方法，有效保证了产品的质量控制。此外，注射用维拉苷酶β也是中国首个通过生物制品分段生产检查的创新生物药。陈智胜博士首席执行官药明生物我们非常荣幸赋能北海康成实现注射用维拉苷酶β获批上市的关键里程碑，这也是中国罕见病药物创新的重要突破。罕见病药物研发之路漫长而艰辛，从实验室的早期发现到最终惠及患者，需要克服无数技术难关和挑战。该产品成功实现从概念到商业化生产，既是北海康成十年如一日深耕罕见病领域的坚守见证，也是药明生物一体化技术平台和CRDMO商业模式的成功实践。双方在解决罕见病患者未满足临床需求方面的同频共振，成就了中国首个本土自主开发的戈谢病酶替代疗法药物。我们期待赋能更多全球合作伙伴加速研发高质量罕见病治疗药物，推动罕见病药物创新，惠及更多罕见病患者。薛群博士创始人董事长兼首席执行官北海康成酶替代疗法是北海康成全球管线布局中非常重要的一部分，注射用维拉苷酶β在中国的获批具有里程碑意义。未来，注射用维拉苷酶β利用平台化技术将大大降低开发成本，让患者用得上、用得起安全、有效的国产酶替代药物。该产品也是北海康成与药明生物在罕见病领域的首个合作项目，在此我们感谢包括药明生物在内的赋能研制和生产这一产品的合作伙伴。这不仅是继海芮思和迈芮倍之后北海康成上市的第三个罕见病治疗药物，也是即将进入商业化的首个自主研发产品。未来我们将持续深耕罕见病药物的本土化研发、生产、上市和可及，为中国患者带来创新的治疗方案。自成立以来，药明生物一直致力于赋能全球创新生物技术公司，加速罕见病治疗药物的上市进程，造福全球罕见病患者。截至2024年底，药明生物平台已支持21个罕见病相关项目。此外，公司还通过一系列公益活动促进公众对罕见疾病的认知，关怀罕见病患者群体。药明生物在全球各地发起了“Run for Health”企业社会责任活动，旨在提升社会对罕见病群体的关注与支持，活动参与总人数超过2500人。公司还在中国设立了“罕见病学生教育支持专项计划”，为受罕见病影响的学生提供奖学金。该计划已实施四年，为逾百名学生提供奖学金及教育礼品包，支持他们的学业发展。 关于注射用维拉苷酶β注射用维拉苷酶β是国内首个本土自主研发并即将进入临床应用的用于治疗I型和III型戈谢病患者的重组人源脑苷脂酶替代疗法。大多数戈谢病患者为I型和III型，分别为慢性非神经病变型和慢性神经病变型。维拉苷酶β通过静脉输注特异性地补充戈谢病患者体内溶酶体中缺乏的葡萄糖脑苷脂酶。维拉苷酶β的关键性临床试验于2024年8月取得积极顶线数据，是一项随机、双盲、剂量比较研究，旨在评估静脉滴注维拉苷酶β每2周一次在初治戈谢病患者中的有效性、安全性和药代动力学，并设有开放标签的扩展期。结果表明，该研究在60U/kg剂量组（P<0.0001）和较低的30U/kg剂量组（P<0.001）都成功达到了其主要疗效终点，即治疗9个月后受试者脾脏体积较基线的平均缩小百分比。该研究方案主要终点的设定已获得国家药品监督管理局药品审评中心(CDE)认可。关于戈谢病（GD）戈谢病是一种最常见的溶酶体贮积症之一，为位于1q22号染色体长臂上的葡萄糖脑苷脂酶基因突变引起的常染色体隐性遗传病。该病对男性和女性的影响是同等的。临床上戈谢病包括围产期致死型、I型（非神经病变型）、II型（急性神经病变型）和III型（慢性神经病变型），其中I型和III型戈谢病患者多能活到成年。戈谢病是由葡萄糖脑苷脂酶（酸性β-葡萄糖苷酶）缺乏引起的，这种酶有助于分解溶酶体内一种被称作葡萄糖脑苷脂（葡糖神经酰胺）的细胞膜鞘脂。葡萄糖脑苷脂主要积聚在某些器官内的单核巨噬细胞系细胞中（Gaucher细胞），导致脾肿大，肝肿大，贫血，血小板减少症，骨痛和骨折，严重的戈谢病类型（围产期致死型，II型和III型），早期可出现神经系统症状。30年以来，重组人源葡萄糖脑苷脂酶替代疗法 (ERT) 一直是戈谢病的标准治疗方法，临床试验和真实世界数据表明，患者的主要非神经系统症状和体征以及生活质量得到了显着改善。根据弗若斯特沙利文的报告数据显示，2020年在中国约有3000名戈谢病患者。目前，戈谢病已被纳入国家《第一批罕见病目录》。关于药明生物药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com关于北海康成北海康成制药有限公司（以下简称“北海康成”，股票代码1228.HK）是一家在中国领先并专注罕见疾病领域的全球化的生物制药公司，致力于创新疗法的研究、开发和商业化。公司目前拥有10个具有可观市场潜力的药物资产组合，其中包括2种已获批上市产品和8个在研药物。这些产品均针对一些较普遍的罕见疾病， 比如亨特综合征（黏多糖贮积症II型）和其他溶酶体贮积症、补体介导的疾病、血友病 A、代谢紊乱、罕见的胆汁淤积性肝病、神经肌肉疾病。北海康成的新一代基因技术研发中心实验室正在开发针对罕见遗传病，包括庞贝氏症、法布雷病、杜氏肌肉营养不良症（DMD）和其他神经肌肉疾病的新型及潜在治愈性的基因疗法，并与世界领先的研究人员和生物技术公司合作。公司的全球合作伙伴包括不限于 Apogenix、GC Pharma、Mirum、药明生物、Privus、华盛顿大学医学部和Scriptr Global 等。如需了解更多关于北海康成制药有限公司的信息，请访问：http://www.canbridgepharma.com/  业务垂询        info@wuxibiologics.com媒体关系  PR@wuxibiologics.com注：本信息不构成药明生物的信息披露或投资建议请点击右下角【爱心】，并将公众号设为【星标】，第一时间接收药明生物最新动态